Status:
COMPLETED
The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.
Lead Sponsor:
Ain Shams University
Conditions:
Muscle Relaxation
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight,...
Detailed Description
The aim of this study is compare the reversal of rocuronium induced neuromuscular blockade in morbidly obese patients using three doses of sugammadex; based on ideal body weight, adjusted body weight,...
Eligibility Criteria
Inclusion
- patients older than 18 years and under 45 years,
- body mass index ≥ 40 kg/m2, with indication of bariatric surgery
Exclusion
- Patients with comorbid including: neuromuscular disease, renal impairment, and patients with difficult airway were excluded from this study.
Key Trial Info
Start Date :
June 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03381209
Start Date
June 10 2017
End Date
November 10 2017
Last Update
December 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Ain Shams University
Cairo, Egypt